

Subgroup	Value	Dapagliflozin	Placebo	Hazard Ratio [95% CI]	p-value	p- interaction
		Event n (KM event rate)	Event n (KM event rate)			
Overall		2779 (32.2%)	3036 (34.9%)	0.89 [0.85-0.94]	<0.0001	
Sex	Women	924 (29.0%)	1022 (30.9%)	0.92 [0.84-1.00]	0.052	0.45
	Men	1855 (34.1%)	2014 (37.4%)	0.88 [0.82-0.94]	<0.0001	
Age, years	< 65	1383 (29.8%)	1477 (31.5%)	0.91 [0.85-0.98]	0.012	0.46
	≥ 65	1396 (34.9%)	1559 (38.8%)	0.88 [0.81-0.94]	0.0003	
Race	Non-white	488 (28.7%)	554 (31.4%)	0.88 [0.78-1.00]	0.047	0.89
	White race	2291 (33.0%)	2482 (35.8%)	0.89 [0.84-0.95]	<0.0001	
Region	Asia/Pacific	359 (33.3%)	397 (36.1%)	0.89 [0.77-1.03]	0.11	0.65
	Eastern Europe	856 (30.7%)	949 (33.9%)	0.86 [0.78-0.94]	0.0013	
	Latin America	159 (17.4%)	191 (20.6%)	0.81 [0.66-1.00]	0.049	
	North America	1029 (36.8%)	1079 (38.7%)	0.93 [0.85-1.01]	0.081	
	Western Europe	376 (35.9%)	420 (38.5%)	0.93 [0.81-1.07]	0.28	
Duration of type 2 diabetes, years	≤ 5	557 (29.4%)	586 (29.4%)	0.98 [0.87-1.10]	0.75	0.074
	>5-≤15	1375 (31.0%)	1467 (33.6%)	0.90 [0.83-0.97]	0.0037	
	>15	847 (36.6%)	982 (41.8%)	0.83 [0.76-0.91]	<0.0001	
History of Hypertension	No History of HTN	239 (28.7%)	275 (29.0%)	0.97 [0.81-1.15]	0.72	0.33
	History of HTN	2540 (32.5%)	2761 (35.6%)	0.88 [0.84-0.93]	<0.0001	
History of HF	No History of HF	2378 (30.4%)	2604 (33.2%)	0.89 [0.84-0.94]	<0.0001	0.62
	History of HF	401 (48.3%)	432 (50.0%)	0.93 [0.81-1.06]	0.26	
BMI, kg/m2	≥30	1792 (34.5%)	1896 (37.3%)	0.90 [0.84-0.96]	0.0011	0.66
	< 30	985 (28.7%)	1137 (31.4%)	0.88 [0.80-0.95]	0.0022	
HbA1c, %	<7	253 (30.8%)	288 (34.5%)	0.85 [0.72-1.01]	0.059	0.59
	7-<8	1038 (31.2%)	1157 (34.4%)	0.87 [0.80-0.95]	0.0010	
	8-<9	697 (31.4%)	818 (34.8%)	0.89 [0.80-0.98]	0.023	
	≥9	791 (34.8%)	773 (36.0%)	0.94 [0.85-1.04]	0.25	
eGFR, mL/min/1.73 m2	≥90	1165 (27.8%)	1252 (30.9%)	0.88 [0.81-0.96]	0.0020	0.56
	60-90	1336 (34.8%)	1467 (37.0%)	0.90 [0.83-0.97]	0.0041	
	< 60	277 (45.3%)	317 (47.5%)	0.97 [0.83-1.14]	0.74	
UACR, mg/g	≤15	1286 (27.8%)	1407 (30.4%)	0.89 [0.82-0.96]	0.0025	0.65
	>15-<30	435 (34.2%)	485 (37.6%)	0.89 [0.78-1.01]	0.065	
	30-300	746 (37.0%)	794 (39.1%)	0.92 [0.83-1.02]	0.11	
	>300	254 (43.9%)	289 (49.8%)	0.81 [0.68-0.96]	0.014	
	Low	1577 (28.4%)	1740 (31.3%)	0.88 [0.82-0.94]	0.0002	
KDIGO risk	Moderate	777 (36.6%)	819 (38.3%)	0.93 [0.84-1.03]	0.16	0.74
	High	313 (44.9%)	346 (49.7%)	0.88 [0.76-1.03]	0.11	
	Very high	53 (47.8%)	70 (52.6%)	0.75 [0.52-1.08]	0.13	
	Low KDIGO risk and MRF	781 (22.3%)	901 (25.8%)	0.83 [0.76-0.92]	0.0002	
Cardiovascular and kidney risk	KDIGO risk	1939 (38.8%)	2074 (41.1%)	0.92 [0.86-0.97]	0.0049	0.12
ACEi/ARBs	No	508 (31.6%)	510 (31.5%)	0.99 [0.88-1.12]	0.92	0.062
	Yes	2271 (32.3%)	2526 (35.7%)	0.87 [0.82-0.92]	<0.0001	
Insulin Use	No	1396 (27.6%)	1574 (29.9%)	0.89 [0.83-0.96]	0.0020	0.68
	Yes	1383 (38.6%)	1462 (42.4%)	0.88 [0.81-0.94]	0.0004	

